UQ1 Stock Overview
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
uniQure N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.58 |
52 Week High | US$20.05 |
52 Week Low | US$4.23 |
Beta | 0.96 |
1 Month Change | -18.21% |
3 Month Change | -16.58% |
1 Year Change | -74.85% |
3 Year Change | -81.57% |
5 Year Change | -91.11% |
Change since IPO | -64.16% |
Recent News & Updates
Recent updates
Shareholder Returns
UQ1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 8.4% | 4.5% | 1.4% |
1Y | -74.8% | 34.1% | 7.5% |
Return vs Industry: UQ1 underperformed the German Biotechs industry which returned 34.1% over the past year.
Return vs Market: UQ1 underperformed the German Market which returned 7.5% over the past year.
Price Volatility
UQ1 volatility | |
---|---|
UQ1 Average Weekly Movement | 10.7% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UQ1's share price has been volatile over the past 3 months.
Volatility Over Time: UQ1's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 480 | Matt Kapusta | https://www.uniqure.com |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.
uniQure N.V. Fundamentals Summary
UQ1 fundamental statistics | |
---|---|
Market cap | €233.74m |
Earnings (TTM) | -€285.47m |
Revenue (TTM) | €14.66m |
15.9x
P/S Ratio-0.8x
P/E RatioIs UQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
UQ1 income statement (TTM) | |
---|---|
Revenue | US$15.84m |
Cost of Revenue | US$212.60m |
Gross Profit | -US$196.75m |
Other Expenses | US$111.72m |
Earnings | -US$308.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -6.45 |
Gross Margin | -1,241.90% |
Net Profit Margin | -1,947.09% |
Debt/Equity Ratio | 238.8% |
How did UQ1 perform over the long term?
See historical performance and comparison